<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amiloride: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amiloride: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Amiloride: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8550" href="/d/html/8550.html" rel="external">see "Amiloride: Drug information"</a> and <a class="drug drug_patient" data-topicid="10792" href="/d/html/10792.html" rel="external">see "Amiloride: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708618"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hyperkalemia:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Like other potassium-conserving agents, amiloride may cause hyperkalemia (serum potassium levels greater than 5.5 mEq per liter) which, if uncorrected, is potentially fatal. Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. This incidence is greater in patients with renal impairment, diabetes mellitus (with or without recognized renal insufficiency), and in the elderly. When amiloride is used concomitantly with a thiazide diuretic in patients without these complications, the risk of hyperkalemia is reduced to about 1% to 2%. It is thus essential to monitor serum potassium levels carefully in any patient receiving amiloride, particularly when it is first introduced, at the time of diuretic dosage adjustments, and during any illness that could affect renal function.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865882"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Midamor</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1056427"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Diuretic, Potassium Sparing</span></li></ul></div>
<div class="block dop drugH1Div" id="F133065"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Limited data available: Children and Adolescents: Oral: Initial: 0.4 to 0.625 mg/kg/dose once daily; maximum daily dose: 20 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286277','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286277','lexi-content-ref-NIH.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b3bf4fb-d61c-4d60-acaa-a34bb1a9f68a">Edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema:</b> Limited data available: Children and Adolescents: Oral: 0.625 mg/kg/day divided every 12 to 24 hours; maximum daily dose: 20 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16898855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16898855'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1f6c2a04-c752-45f2-882f-d80001bcab3f">Nephrogenic diabetes insipidus, congenital</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nephrogenic diabetes insipidus, congenital:</b> Limited data available: Infants, Children, and Adolescents: Oral: 0.3 mg/kg/day in divided doses 3 times daily <b>or</b> 20 mg/1.73 m<sup>2</sup>/day in combination with hydrochlorothiazide; dosing based on a retrospective descriptive analysis (n=30, age range: 1 month to 40 years), two pediatric case series (n=4 and n=5), and a case report (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10332005','lexi-content-ref-Kliegman.1','lexi-content-ref-2391611','lexi-content-ref-8251321','lexi-content-ref-10477148']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10332005','lexi-content-ref-Kliegman.1','lexi-content-ref-2391611','lexi-content-ref-8251321','lexi-content-ref-10477148'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dohp drugH1Div" id="F51064718"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doa drugH1Div" id="F133048"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8550" href="/d/html/8550.html" rel="external">see "Amiloride: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d357704e-0ffc-44ea-b3a6-c99bcee40802">Ascites</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ascites (off-label use):</b> Initial: 10 mg twice daily. If no response, increase every 4 days in increments of 10 mg twice daily to a maximum dosage of 30 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8276370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8276370'])">Ref</a></span>). American Association for the Study of Liver Diseases (AASLD) guidelines recommend a dosage range of 10 to 40 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Runyon.2012','lexi-content-ref-20633946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Runyon.2012','lexi-content-ref-20633946'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not recommended for initial management but may be considered as additional therapy in patients with resistant hypertension who do not respond adequately to optimal combination therapy with preferred agents. An aldosterone receptor antagonist (eg, spironolactone) is typically preferred for resistant hypertension that does not respond to preferred agents; amiloride is an alternative. May be used in patients who develop hypokalemia due to other diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Brook.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Brook.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 mg once daily; evaluate response after ~2 to 4 weeks and increase dose as needed to 10 mg daily in 1 or 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Brook.1','lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Brook.1','lexi-content-ref-Mann.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a637b252-bf4d-4c8a-9030-7744733c13da">Hypokalemia due to chronic stable renal potassium wasting, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypokalemia due to chronic stable renal potassium wasting (eg, certain tubulopathies, chronic kaliuretic diuretic use), treatment (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In patients with renal potassium wasting, amiloride may be more effective and better tolerated than oral potassium supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31706619','lexi-content-ref-Mount.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31706619','lexi-content-ref-Mount.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 to 10 mg once daily; if needed, may gradually increase dose (eg, every 1 to 2 weeks based on serum potassium monitoring) in 5 mg/day increments based on response and tolerability up to 40 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26140272','lexi-content-ref-22901631','lexi-content-ref-25012174','lexi-content-ref-6761369','lexi-content-ref-29534496']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26140272','lexi-content-ref-22901631','lexi-content-ref-25012174','lexi-content-ref-6761369','lexi-content-ref-29534496'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991815"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Manufacturer's labeling: Use of amiloride in patients with diabetes mellitus, SCr &gt;1.5 mg/dL, or BUN &gt;30 mg/dL should be done with caution and careful monitoring; use is contraindicated in patients with anuria, acute or chronic renal insufficiency, or evidence of diabetic nephropathy.</p>
<p style="text-indent:-2em;margin-left:2em;">Alternate recommendations:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 50 mL/minute: Administer at 50% of normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). The Beers Criteria recommends avoiding use in older adults ≥65 years of age with a CrCl &lt;30 mL/minute due to the risk of hyperkalemia and hyponatremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>). The 2017 guideline for the prevention, detection, evaluation, and management of high blood pressure in adults recommends avoiding use in patients with significant chronic kidney disease (eg, GFR &lt;45 mL/minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989094"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F133010"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Central nervous system: Dizziness, fatigue, headache</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Endocrine &amp; metabolic: Hyperkalemia (up to 10%; risk reduced in patients receiving kaliuretic diuretics), dehydration, gynecomastia, hyperchloremic metabolic acidosis, hyponatremia</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Abdominal pain, change in appetite, constipation, diarrhea, gas pain, nausea, vomiting </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Genitourinary: Impotence </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neuromuscular &amp; skeletal: Muscle cramps, weakness </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Respiratory: Cough, dyspnea </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%, postmarketing, and/or case reports: Alopecia, bladder spasm, cardiac arrhythmia, chest pain, dysuria, gastrointestinal hemorrhage, increased intraocular pressure, jaundice, orthostatic hypotension,  palpitations, polyuria </p></div>
<div class="block coi drugH1Div" id="F133025"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to amiloride or any component of the formulation; presence of elevated serum potassium levels (&gt;5.5 mEq/L); if patient is receiving other potassium-conserving agents (eg, spironolactone, triamterene) or potassium supplementation (medicine, potassium-containing salt substitutes, potassium-rich diet) except in severe and/or refractory cases of hypokalemia; anuria; acute or chronic renal insufficiency; evidence of diabetic nephropathy. Patients with evidence of renal impairment (blood urea nitrogen [BUN] &gt;30 mg/dL or serum creatinine &gt;1.5 mg/dL) or diabetes mellitus should not receive amiloride without close, frequent monitoring of serum electrolytes and renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F133007"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid/electrolyte changes: May decrease sodium and chloride and increase BUN, especially with concomitant diuretic therapy; close medical supervision and dose evaluation are required. Watch for and correct electrolyte disturbances; adjust dose to avoid dehydration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: <b>[US Boxed Warning]:</b>
<b> Hyperkalemia (serum potassium levels &gt;5.5 mEq/L) may occur, which can be fatal if not corrected; patients at higher risk include those with renal impairment, diabetes, and the elderly. Serum potassium levels must be monitored at frequent intervals especially when therapy is initiated, when dosages are changed or with any illness that may cause renal dysfunction.</b> Risk of hyperkalemia may be increased when used concomitantly with other medications that may increase potassium (eg, angiotensin agents). Signs/symptoms of hyperkalemia include paresthesias, muscle weakness, fatigue, flaccid paralysis of limbs, bradycardia, shock, and ECG abnormalities. If hyperkalemia occurs, discontinue amiloride immediately and manage hyperkalemia as clinically appropriate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Avoid use of diuretics for treatment of elevated blood pressure in patients with primary adrenal insufficiency (Addison disease). Adjustment of glucocorticoid/mineralocorticoid therapy and/or use of other antihypertensive agents is preferred to treat hypertension (Bornstein 2016; Inder 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cirrhosis: In cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: If possible, avoid use in patients with diabetes mellitus; if cannot be avoided, use with extreme caution and monitor electrolytes and renal function closely. Discontinue amiloride at least 3 days prior to glucose tolerance testing.</p>
<p style="text-indent:-2em;margin-left:4em;">• Metabolic/respiratory acidosis: Use with caution in patients who are at risk for metabolic or respiratory acidosis (eg, cardiopulmonary disease, poorly controlled diabetes); monitor acid base balance frequently.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Amiloride is primarily eliminated renally; patients with renal impairment are at greater risk for toxicities.</p></div>
<div class="block foc drugH1Div" id="F133018"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg</p></div>
<div class="block geq drugH1Div" id="F133003"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F133028"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (aMILoride HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.23 - $1.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865883"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Midamor: 5 mg</p></div>
<div class="block exp drugH1Div" id="F11308003"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 1 mg/mL oral suspension may be made with tablets. Crush ten 5 mg tablets in a mortar and reduce to a fine powder. Add small proportions up to 20 mL of Glycerin BP or Glycerin, USP and mix to uniform paste; mix while adding sterile water in incremental proportions to <b>almost</b> 50 mL; transfer to a calibrated bottle, rinse mortar with sterile water, and add quantity of sterile water sufficient to make 50 mL. Label “shake well” and “refrigerate”. Stable for 21 days.</p>
<div class="reference">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>
</div>
<div class="block admp drugH1Div" id="F52612216"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food or milk</p></div>
<div class="block adm drugH1Div" id="F133022"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food or meals to avoid GI upset.</p></div>
<div class="block sts drugH1Div" id="F28750912"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F). Avoid freezing or excessive heat. Protect from moisture.</p></div>
<div class="block usep drugH1Div" id="F53565332"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Counteracts potassium loss induced by other diuretics in the treatment of hypertension or heart failure; usually used in conjunction with more potent diuretics, such as thiazides or loop diuretics (FDA approved in adults); has also been used for management of edema and congenital nephrogenic diabetes insipidus</p></div>
<div class="block mst drugH1Div" id="F133089"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">AMILoride may be confused with amiodarone, amLODIPine, inamrinone</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Diuretics are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298733"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OCT2</p></div>
<div class="block dri drugH1Div" id="F133012"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: AMILoride may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: Monitor serum potassium concentrations closely. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Potassium-Sparing Diuretics may increase the serum concentration of Lithium. Potassium-Sparing Diuretics may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Diuretics may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: May enhance the hyperkalemic effect of AMILoride. Management: Amiloride and potassium supplements should not be used except in severe or refractory cases of hypokalemia. If coadministered, monitor serum potassium closely as rapid increases in potassium are possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of other Potassium-Sparing Diuretics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: AMILoride may enhance the adverse/toxic effect of QuiNIDine. AMILoride may diminish the therapeutic effect of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F133029"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Do not use potassium-containing salt substitutes.</p></div>
<div class="block rep_considerations drugH1Div" id="F58530475"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Diuretics are second-line agents for the treatment of hypertension in pregnant patients (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019; SOGC [Magee 2022]).</p></div>
<div class="block pri drugH1Div" id="F4930891"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019; SOGC [Magee 2022]); however, data related to the use of amiloride during pregnancy are insufficient and other agents may be preferred (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Case reports describe the use of potassium-sparing diuretics such as amiloride for the adjunctive treatment of Gitleman syndrome during pregnancy (Calò 2012; Moustakakis 2012; Shahzad 2019). Use of amiloride may be considered in some pregnant patients for the treatment of primary aldosteronism (PA). Although data specific to the treatment of PA in pregnancy are limited, adjunctive therapy with amiloride may be initiated in the second or third trimester (ES [Funder 2016]; Forestiero 2022; Sanga 2022).</p></div>
<div class="block mopp drugH1Div" id="F53565333"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum potassium, sodium, creatinine, BUN, blood pressure, fluid balance</p></div>
<div class="block pha drugH1Div" id="F133006"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks epithelial sodium channels in the late distal convoluted tubule (DCT), and collecting duct which inhibits sodium reabsorption from the lumen. This effectively reduces intracellular sodium, decreasing the function of Na+/K+ATPase, leading to potassium retention and decreased calcium, magnesium, and hydrogen excretion. As sodium uptake capacity in the DCT/collecting duct is limited, the natriuretic, diuretic, and antihypertensive effects are generally considered weak. </p></div>
<div class="block phk drugH1Div" id="F133024"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Within 2 hours; Peak effect: 6 to 10 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: ~24 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: 30% to 90% (Macfie 1981)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 350 to 380 L (Macfie 1981)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: Minimal (Macfie 1981)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Does not undergo hepatic metabolism</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Normal renal function: 6 to 9 hours; Renal impairment (CrCl &lt;50 mL/minute): 21 to 144 hours (George 1980)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 3 to 4 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~50%; as unchanged drug); feces (~40%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F133030"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bisdiur</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Midamor</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Kaluril | Midamor | Midoride</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Midamor</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Amiloride | Bi da shu | Wu dou li</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Amiclaran</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Amiloride | Modamide</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Medamor | Puritrid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Modamide</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Amiloride | Amiloride almus | Amiloride aps | Amiloride arrow | Amiloride astec | Amiloride berk | Amiloride cox | Amiloride dc | Amiloride kent | Amiloride sandoz | Amiloride wyeth | Amilospare | Midamor</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Midamor</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Amiloride | Puritrid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Amiloride</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Amiur</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Amilo | Korasik | Ride</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Amiclaran | Amiloride | Midamor</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Amiclaran | Midamor</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Amiloride</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Amikal | Amiloride par pharmaceutical | Midamor | Modamide | Nirulid</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Midamor</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Amiclaran | Midamor | Modamide</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Amiloride HCL | Midamor</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Amilorid Merck NM | Amilorid mylan | Midamor</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Amiclaran</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Amiloride</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Amitride | Edepin | Kaluril</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Amiloride</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26140272">
<a name="26140272"></a>Al Shibli A, Narchi H. Bartter and Gitelman syndromes: spectrum of clinical manifestations caused by different mutations. <i>World J Methodol</i>. 2015;5(2):55-61. doi:10.5662/wjm.v5.i2.55<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/26140272/pubmed" id="26140272" target="_blank">26140272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amiloride.1">
<a name="Amiloride.1"></a>Amiloride [prescribing information]. Bensalem, PA: Sigmapharm Laboratories LLC; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8276370">
<a name="8276370"></a>Angeli P, Dalla Pria M, De Bei E, et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. <i>Hepatology</i>. 1994;19(1):72-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/8276370/pubmed" id="8276370" target="_blank">8276370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22901631">
<a name="22901631"></a>Asmar A, Mohandas R, Wingo CS. A physiologic-based approach to the treatment of a patient with hypokalemia. <i>Am J Kidney Dis</i>. 2012;60(3):492-497. doi:10.1053/j.ajkd.2012.01.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/22901631/pubmed" id="22901631" target="_blank">22901631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25012174">
<a name="25012174"></a>Blanchard A, Vargas-Poussou R, Vallet M, et al. Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. <i>J Am Soc Nephrol</i>. 2015;26(2):468-475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/25012174/pubmed" id="25012174" target="_blank">25012174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26760044">
<a name="26760044"></a>Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi:10.1210/jc.2015-1710<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/26760044/pubmed" id="26760044" target="_blank">26760044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brook.1">
<a name="Brook.1"></a>Brook RD, Townsend RR. Treatment of resistant hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21999963">
<a name="21999963"></a>Calò LA, Caielli P. Gitelman's syndrome and pregnancy: new potential pathophysiological influencing factors, therapeutic approach and materno-fetal outcome. <i>J Matern Fetal Neonatal Med</i>. 2012;25(8):1511-1513. doi:10.3109/14767058.2011.629254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/21999963/pubmed" id="21999963" target="_blank">21999963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31706619">
<a name="31706619"></a>Clase CM, Carrero JJ, Ellison DH, et al; Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney Int</i>. 2020;97(1):42-61. doi:10.1016/j.kint.2019.09.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/31706619/pubmed" id="31706619" target="_blank">31706619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29653741">
<a name="29653741"></a>European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. <i>J Hepatol</i>. 2018;69(2):406-460.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/29653741/pubmed" id="29653741" target="_blank">29653741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20633946">
<a name="20633946"></a>European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. <i>J Hepatol</i>. 2010;53(3):397-417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/20633946/pubmed" id="20633946" target="_blank">20633946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22084329">
<a name="22084329"></a>Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute (NHLBI). Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. <i>Pediatrics</i>. 2011;128(Suppl 5):S213-S256. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/22084329/pubmed" id="22084329" target="_blank">22084329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35536535">
<a name="35536535"></a>Forestiero V, Sconfienza E, Mulatero P, Monticone S. Primary aldosteronism in pregnancy. <i>Rev Endocr Metab Disord</i>. Published online May 10, 2022. doi:10.1007/s11154-022-09729-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/35536535/pubmed" id="35536535" target="_blank">35536535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7356897">
<a name="7356897"></a>George CF. Amiloride handling in renal failure. <i>Br J Clin Pharmacol. 1980;9(1):94-95.</i>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/7356897/pubmed" id="7356897" target="_blank">7356897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6761369">
<a name="6761369"></a>Griffing GT, Aurecchia SA, Sindler BH, Melby JC. The effect of amiloride on the renin-aldosterone system in primary hyperaldosteronism and Bartter's syndrome. <i>J Clin Pharmacol</i>. 1982a;22(11-12):505-512. doi:10.1002/j.1552-4604.1982.tb02643.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/6761369/pubmed" id="6761369" target="_blank">6761369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7075119">
<a name="7075119"></a>Griffing GT, Komanicky P, Aurecchia SA, Sindler BH, Melby JC. Amiloride in Bartter's syndrome. <i>Clin Pharmacol Ther</i>. 1982b;31(6):713-718. doi:10.1038/clpt.1982.100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/7075119/pubmed" id="7075119" target="_blank">7075119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25138826">
<a name="25138826"></a>Inder WJ, Meyer C, Hunt PJ. Management of hypertension and heart failure in patients with Addison's disease. <i>Clin Endocrinol (Oxf)</i>. 2015;82(6):789-792. doi:10.1111/cen.12592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/25138826/pubmed" id="25138826" target="_blank">25138826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6112601">
<a name="6112601"></a>Jaffey L, Martin A. Malignant hyperkalaemia after amiloride/hydrochlorothiazide treatment. <i>Lancet</i>. 1981;1(8232):1272. doi:10.1016/s0140-6736(81)92450-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/6112601/pubmed" id="6112601" target="_blank">6112601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. <i>JAMA</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10332005">
<a name="10332005"></a>Kirchlechner V, Koller DY, Seidl R, Waldhauser F. Treatment of nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride. <i>Arch Dis Child</i>. 1999;80(6):548-552.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/10332005/pubmed" id="10332005" target="_blank">10332005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2849182">
<a name="2849182"></a>Kleyman TR, Cragoe EJ Jr. The Mechanism of Action of Amiloride. <i>Semin Nephrol</i>. 1988;8(3):242-248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/2849182/pubmed" id="2849182" target="_blank">2849182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2391611">
<a name="2391611"></a>Knoers N, Monnens LA. Amiloride-hydrochlorothiazide versus indomethacin-hydrochlorothiazide in the treatment of nephrogenic diabetes insipidus. <i>J Pediatr</i>. 1990;117(3):499-502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/2391611/pubmed" id="2391611" target="_blank">2391611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7274028">
<a name="7274028"></a>Macfie HL, Colvin CL, Anderson PO. New drug evaluations amiloride (Midamor, Merck, Sharp and Dohme). <i>Drug Intell Clin Pharm</i>. 1981;15(2):94-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/7274028/pubmed" id="7274028" target="_blank">7274028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23355577">
<a name="23355577"></a>Mathen S, Venning M, Gillham J. Outpatient management of Gitelman's syndrome in pregnancy. <i>BMJ Case Rep</i>. 2013;2013:bcr2012007927. doi:10.1136/bcr-2012-007927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/23355577/pubmed" id="23355577" target="_blank">23355577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mount.1">
<a name="Mount.1"></a>Mount DB. Clinical manifestations and treatment of hypokalemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26064481">
<a name="26064481"></a>Moustakakis MN, Bockorny M. Gitelman syndrome and pregnancy. <i>Clin Kidney J</i>. 2012;5(6):552-555. doi:10.1093/ckj/sfs126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/26064481/pubmed" id="26064481" target="_blank">26064481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8485017">
<a name="8485017"></a>Murdoch DL, Forrest G, Davies DL, McInnes GT. A comparison of the potassium and magnesium-sparing properties of amiloride and spironolactone in diuretic-treated normal subjects. <i>Br J Clin Pharmacol</i>. 1993;35(4):373-378. doi:10.1111/j.1365-2125.1993.tb04153.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/8485017/pubmed" id="8485017" target="_blank">8485017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. <i>Pediatrics</i>. 2004;114(2)(suppl):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Clinical Practice Guidelines, 2011. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>. Date accessed: June 11, 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.2012">
<a name="Runyon.2012"></a>Runyon BA; American Association for the Study of Liver Diseases Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: Update 2012. <i>Hepatology</i>. https://www.aasld.org/sites/default/files/2019-06/141020_Guideline_Ascites_4UFb_2015.pdf. Accessed April 24, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35686552">
<a name="35686552"></a>Sanga V, Rossitto G, Seccia TM, Rossi GP. Management and outcomes of primary aldosteronism in pregnancy: a systematic review. <i>Hypertension</i>. 2022:101161HYPERTENSIONAHA12118858. doi:10.1161/HYPERTENSIONAHA.121.18858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/35686552/pubmed" id="35686552" target="_blank">35686552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30867665">
<a name="30867665"></a>Shahzad MA, Mukhtar M, Ahmed A, Ullah W, Saeed R, Hamid M. Gitelman syndrome: a rare cause of seizure disorder and a systematic review. <i>Case</i>
<i>Rep Med</i>. 2019;2019:4204907. doi:10.1155/2019/4204907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/30867665/pubmed" id="30867665" target="_blank">30867665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29534496">
<a name="29534496"></a>Tetti M, Monticone S, Burrello J, et al. Liddle syndrome: review of the literature and description of a new case. <i>Int J Mol Sci</i>. 2018;19(3):812. doi:10.3390/ijms19030812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/29534496/pubmed" id="29534496" target="_blank">29534496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8251321">
<a name="8251321"></a>Uyeki TM, Barry FL, Rosenthal SM, Mathias RS. Successful treatment with hydrochlorothiazide and amiloride in an infant with congenital nephrogenic diabetes insipidus. <i>Pediatr Nephrol</i>. 1993;7(5):554-556.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/8251321/pubmed" id="8251321" target="_blank">8251321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16898855">
<a name="16898855"></a>van der Vorst MM, Kist JE, van der Heijden AJ, et al. Diuretics in Pediatrics: Current Knowledge and Future Prospects. <i>Paediatr Drugs</i>. 2006;8(4):245-264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/16898855/pubmed" id="16898855" target="_blank">16898855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10477148">
<a name="10477148"></a>van Lieburg AF, Knoers NV, Monnens LA. Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. <i>J Am Soc Nephrol</i>. 1999;10(9):1958-1964.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/10477148/pubmed" id="10477148" target="_blank">10477148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. <i>Hypertension</i>. 2018;71(6):e13‐e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiloride-pediatric-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 12556 Version 226.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
